<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02766231</url>
  </required_header>
  <id_info>
    <org_study_id>K-09</org_study_id>
    <nct_id>NCT02766231</nct_id>
  </id_info>
  <brief_title>Physica CR and PS Clinical Trial</brief_title>
  <official_title>A Multicentre, Prospective Study Evaluating Clinical, Radiographic and Patient-reported Outcomes of Total Knee Arthroplasty With Physica CR or Physica PS Prosthesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Limacorporate S.p.a</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Limacorporate S.p.a</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type &amp; Design:&#xD;
&#xD;
      Post-market, international, multicentre Prospective, parallel groups, open-label, baseline&#xD;
      controlled&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        1. Assessment of clinical, radiographic and patient-reported outcomes of Physica CR and PS&#xD;
           designs&#xD;
&#xD;
        2. Incidence of adverse events and identification of possible risk factors for&#xD;
           unsatisfactory results&#xD;
&#xD;
        3. Mid-term survivorship of the implants&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical change in Knee Society Score (KSS)</measure>
    <time_frame>from preoperative (baseline) to 5 years after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical change in Knee Society Score (KSS)</measure>
    <time_frame>preoperatively (baseline), 3 months, 6 months, 1 year, 2 years, 3 years after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional change in Timed up and Go (TUG) test</measure>
    <time_frame>preoperatively (baseline), 3 months, 6 months, 1 year, 2 years, 3 years and 5 years after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Knee injury and Osteoarthritis Outcome Score (KOOS)</measure>
    <time_frame>preoperatively (baseline), 3 months, 6 months, 1 year, 2 years, 3 years and 5 years after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Satisfaction Visual Analogue Scale (Satisfaction VAS)</measure>
    <time_frame>3 months (baseline), 6 months, 1 year, 2 years, 3 years, 4 years and 5 years after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forgotten Joint Score (FJS-12)</measure>
    <time_frame>3 months (baseline), 6 months, 1 year, 2 years, 3 years, 4 years and 5 years after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thickness and location of symptomatic radiolucent lines</measure>
    <time_frame>0 months (baseline), 3 months, 6 months, 1 year, 2 years, 3 years and 5 years after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate (Kaplan-Meier)</measure>
    <time_frame>3 years and 5 years after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of device-related AE/SAE</measure>
    <time_frame>0 months, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years after surgery</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Physica CR</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Physica PS</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Physica CR</intervention_name>
    <description>Cruciate tretaining total knee replacement</description>
    <arm_group_label>Physica CR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Physica PS</intervention_name>
    <description>Posterior Stabilized total knee replacement</description>
    <arm_group_label>Physica PS</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        General population of subjects requiring a primary TKR with a diagnosis of painful primary&#xD;
        or secondary osteoartrithis not responding to other conservative treatments, after the&#xD;
        review of medical history and the radiographic evaluation of the affected knee.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and females&#xD;
&#xD;
          2. Age 22-78 years&#xD;
&#xD;
          3. Any race&#xD;
&#xD;
          4. Ambulatory patients&#xD;
&#xD;
          5. Patients who have a medical condition with over 5 years of life expectancy&#xD;
&#xD;
          6. Patients with painful primary or secondary knee osteoarthritis&#xD;
&#xD;
          7. Patients who have undamaged and functional collateral and posterior cruciate ligaments&#xD;
             for the group requiring Physica CR or Patients who have undamaged and functional&#xD;
             collateral ligaments for the group requiring Physica PS&#xD;
&#xD;
          8. Patients with flexion ≥90° on the affected side&#xD;
&#xD;
          9. Patients with a fixed flexion contracture &lt;20°&#xD;
&#xD;
         10. Patients who understand the conditions of the study and are willing and able to comply&#xD;
             with the prescribed rehabilitation and to perform all scheduled follow-up visits&#xD;
&#xD;
         11. Patients who have signed the Ethics Committee approved study-specific Informed Consent&#xD;
             Form prior to the surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous partial knee replacement or patellofemoral joint replacement and previous&#xD;
             patellectomy&#xD;
&#xD;
          2. Primary Total Knee Replacement (TKR) in the affected knee&#xD;
&#xD;
          3. Varus deformity &gt;20° or Valgus deformity &gt;15°&#xD;
&#xD;
          4. Patients with a fixed flexion contracture &gt;20°&#xD;
&#xD;
          5. Previous intra-articular fractures of the affected knee&#xD;
&#xD;
          6. Patients with previous methaphysal tibial or femoral osteotomy performed less than 5&#xD;
             years before the screening visit, in case of plate removal surgery it is done early&#xD;
             than 1 year ago to screening.&#xD;
&#xD;
          7. Previous knee replacement on the contralateral side within the last year and whose&#xD;
             outcome is achieving an KSS&lt; 60 points&#xD;
&#xD;
          8. Patients with symptomatic Osteoarthritis (OA) of the spine if the assessment of pain&#xD;
             with Numeric Rating Scale is &gt;4&#xD;
&#xD;
          9. Patients with an history of infections (on the affected knee or systemic)&#xD;
&#xD;
         10. Muscular insufficiency or absence of muscoligamentous supporting structures required&#xD;
             for adequate soft tissue balance&#xD;
&#xD;
         11. Patients who have damaged or absence of the posterior cruciate ligament for the group&#xD;
             requiring Physica CR&#xD;
&#xD;
         12. Patients with known or suspicious metal hypersensitivity&#xD;
&#xD;
         13. Recurrent medical history of severe allergic or immune-mediated reactions&#xD;
&#xD;
         14. Vascular insufficiency of lower limbs severe enough to interfere with the study&#xD;
             evaluation&#xD;
&#xD;
         15. Current treatment or treatment within the previous 2 years before the screening visit&#xD;
             for malignant and life-threatening non-malignant disorders&#xD;
&#xD;
         16. Any clinically significant pathology based on clinical history that the Investigator&#xD;
             feels may affect the study evaluation including:&#xD;
&#xD;
               1. any intercurrent chronic disease or condition that may interfere with the&#xD;
                  completion of the 5-year follow-up, such as liver disease, severe coronary&#xD;
                  disease, drug or alcohol abuse&#xD;
&#xD;
               2. significant neurological or musculoskeletal disorders or disease that may&#xD;
                  adversely affect gait and compromise functional recovery&#xD;
&#xD;
               3. neuromuscular or neurosensory deficit which would limit the ability to assess the&#xD;
                  performance of the device&#xD;
&#xD;
               4. known metabolic disorders leading to progressive bone deterioration&#xD;
&#xD;
         17. Patients who have known co-existent medical condition with less 5 years of life&#xD;
             expectancy&#xD;
&#xD;
         18. Previous organ transplant surgery&#xD;
&#xD;
         19. Any psychiatric illness that would prevent comprehension of the details and nature of&#xD;
             the study&#xD;
&#xD;
         20. Participation in any experimental drug/device study within the 6 months prior to the&#xD;
             screening visit&#xD;
&#xD;
         21. Female patients who are pregnant, nursing, or planning a pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Peretti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>I.R.C.C.S. Galeazzi (Milan, Italy)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Federica Azzimonti</last_name>
    <email>federica.azzimonti@limacorporate.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc ASBL</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Thienpont</last_name>
    </contact>
    <investigator>
      <last_name>Emmanuel Thienpont</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.R.C.C.S. Galeazzi</name>
      <address>
        <city>Milano</city>
        <zip>20161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Peretti</last_name>
      <email>giuseppe.peretti@unimi.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Peretti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Casa di cura Citta' di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Adravanti</last_name>
    </contact>
    <investigator>
      <last_name>Paolo Adravanti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique d'Eich - centre Hospitalier de Luxembourg</name>
      <address>
        <city>Luxembourg</city>
        <zip>1460</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain Seil</last_name>
    </contact>
    <investigator>
      <last_name>Romain Seil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Luxembourg</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 4, 2016</study_first_submitted>
  <study_first_submitted_qc>May 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2016</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

